CSO Dr Amrik Basran to present on Affimer bispecifics at upcoming International Drug Discovery Science and Technology Conference in Kyoto, Japan July 25th-27th. “Affimer Therapeutics: A novel human protein scaffold
Adding Imfinzi (durvalumab) to standard first-line chemotherapy led to a clinically meaningful extension in the overall survival of patients with advanced small cell lung cancer (SCLC), according to results of
The Affimer is a revolutionary new engineered affinity protein. This video animation gives an overview of some of the key benefits, features and applications of Affimer technology. It explains why
Alastair Smith, Avacta Group Chief Executive Officer, commented: “The strategic partnership with Selexis allows Avacta to access the technology and know-how to develop high-expressing CHO cell lines as well as
Cancer immunotherapy involves empowering the patient’s immune system to recognize, attack and destroy cancer cells. Since cancer cells arise from healthy cells, it can be hard for the immune system to differentiate
Avacta Group Plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has today announced that the Group’s Chief Executive, Alastair Smith, will be presenting at an investor evening hosted by Turner Pope Investments on Wednesday,
Oncologist Dr Harold Burstein said: ‘We are in a golden age of cancer treatment’ Results on cancer drugs were shared at American Society For Clinical Oncology Studies on immunotherapy drugs
Avacta Group’s Alistair Smith discusses the significance of the clinical candidate selection in this exclusive interview with DirectorsTalk
Avacta Group Plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, today announced that its Chief Scientific Officer, Dr Amrik Basran, will be presenting at the Next Generation Protein Therapeutics & Bioconjugates
Avacta Group plc (LON: AVCT) CEO Alastair Smith joins DirectorsTalk to discuss the selection of its first-time-in-human clinical candidate for the Affimer platform. Alastair explains the significance of this news,
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
